LAG3 and cancer: To take a step towards investigating the feasibility of ex vivo gene therapy, we used Cas9-HiFi RNP to introduce a nucleotide substitution in LAG3, a gene often modified to optimize chimeric antigen receptor-T cells for cancer treatment50.